Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 182-187

  Barnett, Mitchell J ^a,b   Perry, Paul J ^b   Alexander, Bruce ^a,b   Kaboli, Peter J ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GOVERNMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MORTALITY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL;

AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HEALTH SERVICES FOR THE AGED; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; PNEUMONIA; RISK FACTORS; SURVIVAL ANALYSIS; TRANQUILIZING AGENTS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 33646698410     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203598.43314.34     Document Type: Article

References (32)

1. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous & Mental Disease. 2004;192:19-27.
2. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry. 2001;58:1161-1167.
3. Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Journal of Clinical Psychiatry. 2001;62 (Suppl 2):35-40.
4. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine. 2005;165:696-701.
5. Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs. 2003;17:307-324.
6. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
7. Advisory FPH. Deaths with antipsychotics in elderly patients with behavioral disturbances. 2005 vol.
8. Lamoreaux J. The organizational structure for medical information management in the Department of Veterans Affairs. An overview of major health care databases. Medical Care. 1996;34:MS31-44.
9. Beattie M, Swindle R, Tomko L, et al. Department of Veterans Affairs Databases Resource Guide: Volume II: Patient Treatment File. Palo Alto, CA: HSR&D Center for Health Care Evaluation, Department of Veterans Affairs Medical Center; 1996.
10. The Pharmacy Benefits Management Strategic Healthcare Group, Department of Veterans Affairs, http://vaww.pbm.med.va.gov/natform/ vaclass.htm; 2002.
11. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical Care. 1998;36:8-27.
12. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Medical Care. 2004;42:355-360.
13. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorders. 2004;6:368-373.
14. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis.[see comment]. Psychosomatic Medicine. 2004;66:802-813.
15. Gump BB, Matthews KA, Eberly LE, et al. Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke. 2005;36:98-102.
16. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry. 2004;161:1334-1349.
17. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. Journal of Affective Disorders. 2002;72:227-236.
18. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
19. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817-830.
20. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. Journal of Clinical Psychopharmacology. 2003;23:58-77.
21. Greenberg HE, Scharf SM, Green H. Nortriptyline-induced depression of ventilatory control in a patient with chronic obstructive pulmonary disease. American Review of Respiratory Disease. 1993;147:1303-1305.
22. McLaren K, Marangell L. Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Annals of General Hospital Psychiatry. 2004;3:1-10.
23. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine. 2004;164:1293-1297.
24. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070.
25. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thrombosis & Haemostasis. 2002;88:205-209.
26. Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiology & Drug Safety. 2003;12:647-652.
27. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. [see comment]. American Journal of Geriatric Psychiatry. 2004;12:437-439.
28. Lamers LM. Health-based risk adjustment: is inpatient and outpatient diagnostic information sufficient? Inquiry. 2001;38:423-431.
29. Iezzoni LI. The risks of risk adjustment. [see comment]. JAMA. 1997;278:1600-1607.
30. Ash A, Schwartz M. Evaluating the performance of risk-adjustment methods: dichotomous measures. In: Iezzoni LI, ed. Risk Adjustment for Measuring Health Care Outcomes. 2nd ed. Health Administration Press: Chicago; 1997:427-470.
31. Kaboli PJ, McClimon BJ, Hoth AB, et al. Assessing the accuracy of computerized medication histories. American Journal of Managed Care. 2004;10:872-877.
32. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia: what should be made of the risks? JAMA. 2005;294:1963-1965.